Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to
that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African
American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate